Results 201 to 209 of about 8,864 (209)

A Single Institution 177Lu-DOTATATE Retreatment Dosimetry Experience

International Journal of Radiation Oncology*Biology*Physics
S.R. Miller, Z. Lu, K. Fitzpatrick, M. Roseland, B.L. Viglianti, K.K. Wong, Y. Dewaraja   +6 more
openaire   +1 more source

177Lu-DOTATATE Tedavi Başarısını Etkileyen Faktörlerin Araştırılması

2022
KARAHAN ŞEN, NAZLI PINAR, ÇAPA KAYA, GAMZE, BOZDEMİR, TOLGA CAN   +2 more
openaire   +1 more source

Single vial kit formulation of DOTATATE for preparation of 177Lu-labeled therapeutic radiopharmaceutical at hospital radiopharmacy

Journal of Labelled Compounds and Radiopharmaceuticals, 2015
Haladhar Dev Sarma, Ashutosh Dash, Archana Mukherjee   +2 more
exaly  

Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL)

Hormone and Metabolic Research, 2012
Francesca Schiavi, Maddalena Sansovini, Giuseppe Opocher   +2 more
exaly  

Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.

Oncology (issn:14230232)
openaire   +1 more source

Radiation exposure of the spleen during 177Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume

EJNMMI Physics, 2016
Johanna Svensson, Peter Bernhardt, Bo Wängberg   +2 more
exaly  

Treatment with 177Lu-DOTATATE: Past, present and future.

Revista espanola de medicina nuclear e imagen molecular, 2018
openaire   +1 more source

Renal Dosimetry for 177Lu-DOTATATE: Impact of Region of Interest Selection

International Journal of Radiation Oncology*Biology*Physics
B. Driscoll, M. Zhou, R.K. Wong, A. Shessel, I.W.T. Yeung   +4 more
openaire   +1 more source

SSA therapies—177Lu-DOTATATE is a better one in NETTER-1

Nature Reviews Clinical Oncology, 2015
openaire   +1 more source